Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
CA 2454059 A1 · Owner: Ibrahim, Prabha · Inventors: Rehder, Kenneth; Elzein, Elfatih; Zablocki, Jeff
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are novel heterocyclic derivatives of the formula (I) wherein , amongst others R1, R2, R3, R4 R5, R6, R7, and R8 are hydrogen; T is oxygen sulfur, or NR11, in which R11 is hydrogen or lower alkyl; V is N< -CH<, or N-, CH<; X1 is hydrogen, optionally substituted lower alkyl optionally , substituted cycloalkyl, optionally substituted aryl or optionally substituted , heteroaryl; X2 is optionally substituted aryl or optionally substituted heteroaryl; Y is optionally substituted monocyclic heteroarylenyl; and Z1 and Z2 are independently optionally substituted alkylene or 1-4 carbon atoms. The compounds are useful for the treatment of various disease states in , particular …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 18, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 18, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 18, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.